Catalyst Pharmaceuticals Inc. (CPRX)
$31.26
$-0.02
(-0.06%)
As on 22-May-2026 18:51EDT
Market cap
$3,826 Mln
Revenue (TTM)
$597 Mln
P/E Ratio
18.1
P/B Ratio
3.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
29.94
-
EV/EBITDA
10
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$1.7
-
Face value
--
-
Shares outstanding
122,380,992
10 Years Aggregate
CFO
$311.30 Mln
EBITDA
$241.97 Mln
Net Profit
$194.60 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
| 33.9 | 21.9 | 28.6 | 28.5 | 37.0 | 40.5 | 48.5 |
|
BSE Sensex*
| -9.7 | -0.2 | -7.0 | -6.4 | 7.4 | 8.6 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
| 11.8 | 23.9 | -9.6 | 174.7 | 102.7 | -10.9 | 95.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
31.3 | 3,825.6 | 597.0 | 221.3 | 46.1 | 22.9 | 18.1 | 3.8 |
| 41.0 | 5,252.7 | 1,105.3 | 133.3 | 15.9 | 32.7 | 38.3 | 12.7 | |
| 236.0 | 12,143.0 | 708.2 | -188.3 | -25.6 | -293.5 | -- | 222.5 | |
| 69.1 | 13,537.9 | 580.0 | -725.9 | -105.2 | -- | -- | 123.7 | |
| 60.2 | 6,464.7 | 769.1 | 47.9 | 5.4 | 7.5 | 172.1 | 10.0 | |
| 13.6 | 11,312.8 | 353,471.6 | 45,087.2 | 16.1 | 12.8 | 26.1 | 2.9 | |
| 21.7 | 10,413.5 | 4,893.0 | -242.0 | -1.5 | -3.7 | -- | 1.5 | |
| 8.0 | 5,431.0 | 7,447.6 | 415.6 | 16.2 | 6.6 | 11.2 | 0.9 | |
| 229.3 | 4,596.0 | 274.5 | 153.6 | 76.6 | 15.8 | 29.9 | 4.6 | |
| 61.0 | 5,422.8 | 288.1 | 22.3 | 17.5 | 34.1 | 358.7 | 49.9 |
Shareholding Pattern
View DetailsAbout Catalyst Pharmaceuticals (CPRX)
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with... lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Read more
-
Co-Founder & Chairman
Mr. Patrick J. McEnany
-
Co-Founder & Chairman
Mr. Patrick J. McEnany
-
Headquarters
Coral Gables, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Catalyst Pharmaceuticals (CPRX)
What is the current share price of Catalyst Pharmaceuticals Inc (CPRX) Today?
The share price of Catalyst Pharmaceuticals Inc (CPRX) is $31.26 (NASDAQ) as of 22-May-2026 18:51 EDT. Catalyst Pharmaceuticals Inc (CPRX) has given a return of 36.95% in the last 3 years.
What is the current PB & PE ratio of Catalyst Pharmaceuticals Inc (CPRX)?
The P/E ratio of Catalyst Pharmaceuticals Inc (CPRX) is 18.07 times as on 22-May-2026, a 40 discount to its peers’ median range of 29.94 times.
The P/B ratio of Catalyst Pharmaceuticals Inc (CPRX) is 3.78 times as on 22-May-2026, a 38 discount to its peers’ median range of 6.06 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
13.86
|
3.11
|
|
2024
|
16.08
|
3.62
|
|
2023
|
26.78
|
4.93
|
|
2022
|
25.42
|
7.03
|
|
2021
|
18.68
|
3.57
|
What is the 52 Week High and Low of Catalyst Pharmaceuticals Inc (CPRX)?
The 52-week high and low of Catalyst Pharmaceuticals Inc (CPRX) are Rs 32.56 and Rs 19.05 as of 25-May-2026.
What is the market cap of Catalyst Pharmaceuticals Inc (CPRX)?
Catalyst Pharmaceuticals Inc (CPRX) has a market capitalisation of $ 3,826 Mln as on 22-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Catalyst Pharmaceuticals Inc (CPRX)?
Before investing in Catalyst Pharmaceuticals Inc (CPRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.